Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation

Background and Purpose: RAS mutations limit the effectiveness of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in combination with chemotherapy for metastatic colorectal cancer (mCRC) patients. Therefore, new cell death forms have focused on identifying indirect targets to inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peng, Li, Xuejie, Zhang, Ruonan, Liu, Shuiping, Xiang, Yu, Zhang, Mingming, Chen, Xiaying, Pan, Ting, Yan, Lili, Feng, Jiao, Duan, Ting, Wang, Da, Chen, Bi, Jin, Ting, Wang, Wengang, Chen, Liuxi, Huang, Xingxing, Zhang, Wenzheng, Sun, Yitian, Li, Guohua, Kong, Lingpan, Chen, Xiaohui, Li, Yongqiang, Yang, Zuyi, Zhang, Qin, Zhuo, Lvjia, Sui, Xinbing, Xie, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163451/
https://www.ncbi.nlm.nih.gov/pubmed/32308771
http://dx.doi.org/10.7150/thno.44705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163451/
https://www.ncbi.nlm.nih.gov/pubmed/32308771
http://dx.doi.org/10.7150/thno.44705

Ejemplares similares